---
title: A proinflammatory stem cell niche drives myelofibrosis through a targetable
  galectin-1 axis
date: '2024-10-09'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39383242/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20241010184156&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Myeloproliferative neoplasms are stem cell-driven cancers associated
  with a large burden of morbidity and mortality. Most patients present with early-stage
  disease, but a substantial proportion progress to myelofibrosis or secondary leukemia,
  advanced cancers with a poor prognosis and high symptom burden. Currently, it remains
  difficult to predict progression, and therapies that reliably prevent or reverse
  fibrosis are lacking. A major bottleneck to the discovery of disease-modifying ...
disable_comments: true
---
Myeloproliferative neoplasms are stem cell-driven cancers associated with a large burden of morbidity and mortality. Most patients present with early-stage disease, but a substantial proportion progress to myelofibrosis or secondary leukemia, advanced cancers with a poor prognosis and high symptom burden. Currently, it remains difficult to predict progression, and therapies that reliably prevent or reverse fibrosis are lacking. A major bottleneck to the discovery of disease-modifying ...